Courtalam Peetham Uttaradhikari coronation event on June 6
The coronation rituals of Sri Datteshwarananda Bharati Swami as Uttaradhikari of Sri Siddeshwara Peetham in Courtalam in Tamil Nadu in the presence existing pontiff of Sri Siddheswari Peetham Jagadguru Sri Siddheswarananda Bharati Mahaswami will be held on June 6.
Sri Siddheshwari Peetham secretary Srinivas Munipalle in a statement said that Sri Datteshwarananda Bharati Swami, who holds a MBBS degree, served as medical officer in northern India before he took Sanyasa Deeksha and earlier was known as as Dr Kadambari Aravind.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
22 minutes ago
- CNBC
India's macro strength and market breadth signal uptrend, says Motilal Oswal
Gautam Duggad, Head of Research at Motilal Oswal Financial Services, says India's macro fundamentals are at their strongest in decades. He expects the Nifty to edge toward 26,000 by the end of 2025, which would also allow enough time for valuations to "cool off". He is bullish on non-banking financials, capital markets, and quick commerce players, though he remains cautious on EVs and IT services. The biggest risk to the equity outlook, he says, will be on the external front.
Yahoo
22 minutes ago
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
CNA
22 minutes ago
- CNA
Historic defence expenditure enables greater Australian contribution to region's security: Australian DPM
Australian Deputy Prime Minister and Defence Minister Richard Marles details his country's largest peacetime defence spending increase aimed at expanding naval, air and missile capabilities. He emphasises Australia's commitment to collective regional security through enhanced military power and deepening defence partnerships across Southeast Asia and the Pacific.
